查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363243

吸入器市场规模、份额和趋势分析报告：按药物类别、用途、地区和细分市场预测，2023-2030 年

Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

吸入器市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球吸入药物市场规模将超过524亿美元，2023年至2030年年复合成长率为6.6%。

呼吸系统疾病患病的上升和老年人口的增加是预计推动市场发展的一些关键因素。慢性阻塞性肺病（COPD）是一种危及生命的呼吸系统疾病，预计将成为全球第三大死因。这增加了对吸入药物的需求。

根据全球疾病负担研究，2016 年全球报告了 2.51 亿个慢性阻塞性肺病病例。因此，开发新型吸入药物的需求日益增加。例如，2019年1月，维罗纳製药公司获得世界卫生组织核准开发用于慢性阻塞性肺病适应症的恩西芬汀，并完成了第二期临床试验。

吸入药物的进步预计将推动吸入药物市场的发展。正在研究奈米颗粒以开发先进的吸入药物。例如，2019年4月，昆士兰科技大学的科学家利用负载肺癌吸入粉末的壳聚醣奈米颗粒进行了一项研究。这些奈米颗粒可以轻鬆穿透下呼吸道并扩散到血液中。

糖尿病和帕金森氏症等非呼吸系统疾病患病的上升预计也将推动市场的发展。因此，製造商正在开发创新的、具有成本效益的吸入药物。例如，2019 年 1 月，MannKind Corporation 为糖尿病患者开发了 Afrezza 并将其商业化。

强大的管道药物的存在被认为是推动市场成长的关键因素之一。全球整体有超过220个项目正在进行临床试验。例如，葛兰素史克的气喘治疗药物糠酸氟替卡松/维兰特罗/Umeclidinium Bromide三重联合治疗正处于III阶段，很可能在预测期内推出。

公司正在采取联盟、併购、合作伙伴关係和意识计划等策略性倡议，以扩大产品系列在市场上获得更牢固的立足点。例如，2019年7月，Cipla, Inc.与总部位于上海的江苏创诺药业成立了一家合资企业，在中华人民共和国成立一家生产呼吸产品的公司。

吸入药物市场报告亮点

  • 按产品，干粉製剂凭藉其低密度、易在吸入器中分散等优势，将在2022年占据吸入药物市场的主导地位。
  • 从用途来看，由于气喘和慢性阻塞性肺病的高患病，呼吸系统疾病在 2022 年的收益中占据最大的市场占有率。由于各种神经系统疾病的治疗机会较多，非呼吸系统疾病领域正在快速成长。
  • 受成熟的製药业、医疗保健设施以及吸入器使用意识不断增强的推动，北美将在 2022 年占据全球吸入器市场的主导地位。预计亚太市场将在预测期内出现最快的成长。
  • 该行业的主要企业包括阿斯特捷利康、Vectura、西普拉、葛兰素史克、诺华、萌蒂製药、勃林格殷格翰国际和迈兰。

目录

第1章调查方法和范围

第2章执行摘要

第3章吸入药物市场变因、趋势、范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 吸入器市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章吸入药物：药物类别的估计和趋势分析

  • 吸入器市场：要点
  • 吸入药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 气雾剂
  • 干粉配方
  • 喷

第5章吸入器：用途估算与趋势分析

  • 吸入器市场：要点
  • 吸入药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 呼吸系统疾病
  • 非呼吸系统疾病

第6章吸入器市场：区域估计与趋势分析

  • 区域预测
  • 按地区分類的吸入器市场：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd
    • Viatris Inc.
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
Product Code: GVR-3-68038-767-4

Inhalable Drugs Market Growth & Trends:

The global inhalable drugs market size is expected to reach over USD 52.4 billion by 2030, according to a new report by Grand View Research, Inc.., registering a CAGR of 6.6% from 2023 to 2030. Rising prevalence of respiratory diseases and increasing geriatric population are some of the key factors expected to drive the market. Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory ailments, which is projected to become the third leading cause of death globally. This will increase the demand for inhalable drugs.

According to the Global Burden of Disease study, in 2016, 251 million cases of COPD were reported worldwide. Hence, the need for developing new inhalable drugs has increased. For instance, in January 2019, Verona Pharma received WHO approval for developing Ensifentrine indicated for COPD, which has completed Phase II of clinical trials.

Advancements in inhalable drugs is anticipated to propel the inhalable drugsmarket. Nanoparticles are studied for the development of advanced inhalation drugs. For instance, in April 2019, a scientist from Queensland University of Technology conducted a research using chitosan nanoparticles loaded with inhalation powder for lung cancer. These nanoparticles can easily penetrate the lower respiratory tract and can diffuse into the bloodstream.

Rising prevalence of non-respiratory diseases such as diabetes and Parkinson's diseases is also expected to drive the market. Therefore, manufacturers are developing cost-effective and innovative inhalable drugs. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for diabetic patients.

Presence of strong pipeline drugs is considered to be one of the major factors estimated to boost the market growth. There are more than 220 ongoing projects under clinical trials globally. For instance, GlaxoSmithKline's triple combination therapy of Fluticasone Furoate/Vilanterol/Umeclidinium Bromide to treat asthma is in Phase III and is likely to be launched during the forecast period.

Companies are undergoing strategic initiatives such as collaborations, mergers and acquisitions, partnerships, and awareness programs to widen their product portfolio and gain a stronger foothold in the market. For instance, in July 2019, Cipla, Inc. entered into a joint venture with Shanghai-based Jiangsu Acebright Pharmaceuticals to establish a company in the People's Republic of China to manufacture respiratory products.

Inhalable Drugs Market Report Highlights:

  • By product, the dry powder formulation segment dominated the market for inhalable drugs in 2022 owing to benefits such as low density and ability to disperse easily through inhalers
  • Based on application, respiratory diseases held the largest market share in terms of revenue in 2022, due to high prevalence of asthma and COPD. The non-respiratory diseases segment is growing at a rapid pace owing to the high opportunity in management of various neurological disorders
  • North America held the leading position in the global inhalable drugs market for inhalable drugs in 2022, driven by established pharmaceutical industry and healthcare facilities and growing awareness about the use of inhalers. The Asia Pacific market is projected to exhibit the fastest growth during the forecast period.
  • Key players in this industry include AstraZeneca; Vectura, Cipla Inc.; GlaxoSmithKline; Novartis; Mundipharma; Boehringer Ingelheim International GmbH; and Mylan.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Inhalable Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Inhalable Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Inhalable Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Inhalable Drugs Market: Key Takeaways
  • 4.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Aerosol
    • 4.3.1. Aerosol market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Dry Powder Formulation
    • 4.4.1. Dry powder formulation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Spray
    • 4.5.1. Spray market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Inhalable Drugs: Application Estimates & Trend Analysis

  • 5.1. Inhalable Drugs Market: Key Takeaways
  • 5.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Respiratory Diseases
    • 5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-respiratory Diseases
    • 5.4.1. Non-respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Inhalable Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Inhalable Drugs Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AstraZeneca
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Vectura Group Ltd
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Viatris Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. GSK plc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Mundipharma International.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Cipla Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 Europe inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Europe inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 14 UK inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 16 France inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 Italy inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Spain inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 Denmark inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Denmark inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Sweden inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Sweden inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Norway inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Norway inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 Japan inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Japan inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 33 China inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 China inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 35 India inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Australia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Australia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 Thailand inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Thailand inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 South Korea inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 South Korea inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Latin America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Latin America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 Latin America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Brazil inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 48 Mexico inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Mexico inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Argentina inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 UAE inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Kuwait inhalable drugs market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Inhalable drugs: Market outlook
  • Fig. 9 Inhalable drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Inhalable drugs market driver impact
  • Fig. 15 Inhalable drugs market restraint impact
  • Fig. 16 Inhalable drugs market strategic initiatives analysis
  • Fig. 17 Inhalable drugs market: Drug class movement analysis
  • Fig. 18 Inhalable drugs market: Drug class outlook and key takeaways
  • Fig. 19 Aerosol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Dry powder formulation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Spray market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Inhalable drugs market: Application movement analysis
  • Fig. 23 Inhalable drugs market: Application outlook and key takeaways
  • Fig. 24 Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Non-respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global inhalable drugs market: Regional movement analysis
  • Fig. 27 Global inhalable drugs market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)